Q3 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for Illumina in a research report issued on Thursday, April 17th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings per share of $1.05 for the quarter, down from their previous forecast of $1.10. The consensus estimate for Illumina’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina’s Q1 2026 earnings at $1.03 EPS, Q2 2026 earnings at $1.17 EPS, Q3 2026 earnings at $1.30 EPS, Q4 2026 earnings at $1.47 EPS and FY2026 earnings at $4.97 EPS.

Several other brokerages have also recently commented on ILMN. Guggenheim decreased their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Citigroup dropped their target price on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a report on Friday, February 28th. Piper Sandler raised their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Finally, Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $138.70.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $71.21 on Friday. The stock’s fifty day simple moving average is $85.20 and its 200 day simple moving average is $120.80. The stock has a market capitalization of $11.28 billion, a price-to-earnings ratio of -9.27, a PEG ratio of 1.60 and a beta of 1.38. Illumina has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%.

Institutional Investors Weigh In On Illumina

Several large investors have recently modified their holdings of ILMN. Rakuten Securities Inc. boosted its stake in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after buying an additional 270 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the 4th quarter valued at $32,000. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the 4th quarter worth about $40,000. Finally, PFS Partners LLC increased its position in shares of Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 400 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.